fibrosis Archives -

Roche’s idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market,

PureTech challenges Roche’s Esbriet in head-to-head IPF trial

https://pharmaphorum.com/news/puretech-challenges-roches-esbriet-in-head-to-head-ipf-trial/

Digital/ News/ News

Boehringer invests again in AI diagnosis specialist Brainomix

Phil Taylor Boehringer Ingelheim, Brainomix, digital, digital health, fibrosis, financing, Oncology, stroke 0 Comment

UK digital health company Brainomix has raised £16 million ($21.5 million) that will be used to extend the

Boehringer invests again in AI diagnosis specialist Brainomix

https://pharmaphorum.com/news/boehringer-invests-again-in-ai-diagnosis-specialist-brainomix/

Events/ Events/ R&D

5th Antifibrotic Drug Development Summit -AFDD-

Jessica Durston COVID-19, drug development, fibrosis, IPF, NASH 0 Comment

5th Antifibrotic Drug Development Summit -AFDD-

https://pharmaphorum.com/events/5th-antifibrotic-drug-development-summit-afdd/

News/ News/ R&D

NGM craters after dropping mid-stage NASH candidate aldafermin

Phil Taylor fibrosis, hepatology, NASH, NGM Bio 0 Comment

Shares in NGM Biopharma have plummeted after the US biotech said it would abandon development of aldafermin in

NGM craters after dropping mid-stage NASH candidate aldafermin

https://pharmaphorum.com/news/ngm-craters-after-dropping-mid-stage-nash-candidate-aldafermin/

News/ News/ R&D

Gilead/Galapagos alliance hit again as IPF drug is binned

Phil Taylor fibrosis, Galapagos, Gilead Sciences, idiopathic pulmonary fibrosis, partnership, respiratory disease 0 Comment

Gilead and Galapagos’ much-trumpeted R&D alliance has suffered another setback with the abandonment of ziritaxestat after a late-stage

Gilead/Galapagos alliance hit again as IPF drug is binned

https://pharmaphorum.com/news/gilead-galapagos-alliance-hit-again-as-ipf-drug-is-binned/

Events/ Events

Interstitial Lung Disease (ILD) Drug Development Summit

Kaltrina Kastrati fibrosis, lung, patients 0 Comment

Industry Led Conference on Fibrosing ILDs

Interstitial Lung Disease (ILD) Drug Development Summit

https://pharmaphorum.com/events/interstitial-lung-disease-ild-drug-development-summit/

News/ News/ Oncology

BMS swoops on Forbius, snaring another immuno-oncology player

Phil Taylor Bristol-Myers Squibb, fibrosis, Forbius, immuno-oncology, M&A, Oncology 0 Comment

With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development

BMS swoops on Forbius, snaring another immuno-oncology player

https://pharmaphorum.com/news/bms-swoops-on-forbius-snaring-another-immuno-oncology-player/

News/ News/ R&D

BMS, BioMotiv alliance generates biopharma company Anteros

Phil Taylor accelerator, Anteros Pharmaceuticals, BioMotiv, Bristol-Myers Squibb, fibrosis, inflammation, start-up 0 Comment

A partnership between Bristol-Myers Squibb and drug development accelerator BioMotiv has yielded its first fruit just a few

BMS, BioMotiv alliance generates biopharma company Anteros

https://pharmaphorum.com/news/bms-biomotiv-alliance-generates-biopharma-company-anteros/

R&D/ Views & Analysis/ Views and analysis

The promising future of RNA

mike.hammerton@pharmaphorum.com cancer, fibrosis, liver, R&D, Sirnaomics, WuXi 0 Comment

RNA technology-based therapeutics are a new and novel way to treat diseases. RNA medicines utilise biological processes to

The promising future of RNA

https://pharmaphorum.com/r-d/views-analysis-r-d/the-promising-future-of-rna/

Trending

fibrosis

Login